182 related articles for article (PubMed ID: 15160302)
1. Pharmacokinetic-pharmacodynamic analysis of fluoroquinolones against Bacillus anthracis.
Kihira T; Sato J; Shibata T
J Infect Chemother; 2004 Apr; 10(2):97-100. PubMed ID: 15160302
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics-pharmacodynamics of gatifloxacin in a lethal murine Bacillus anthracis inhalation infection model.
Ambrose PG; Forrest A; Craig WA; Rubino CM; Bhavnani SM; Drusano GL; Heine HS
Antimicrob Agents Chemother; 2007 Dec; 51(12):4351-5. PubMed ID: 17875992
[TBL] [Abstract][Full Text] [Related]
3. Post-exposure prophylaxis of systemic anthrax in mice and treatment with fluoroquinolones.
Steward J; Lever MS; Simpson AJ; Sefton AM; Brooks TJ
J Antimicrob Chemother; 2004 Jul; 54(1):95-9. PubMed ID: 15163650
[TBL] [Abstract][Full Text] [Related]
4. Effective antimicrobial regimens for use in humans for therapy of Bacillus anthracis infections and postexposure prophylaxis.
Deziel MR; Heine H; Louie A; Kao M; Byrne WR; Basset J; Miller L; Bush K; Kelly M; Drusano GL
Antimicrob Agents Chemother; 2005 Dec; 49(12):5099-106. PubMed ID: 16304178
[TBL] [Abstract][Full Text] [Related]
5. Fluoroquinolone benchmarking in relation to pharmacokinetic and pharmacodynamic parameters.
Paladino JA; Callen WA
J Antimicrob Chemother; 2003 May; 51 Suppl 1():43-7. PubMed ID: 12702703
[TBL] [Abstract][Full Text] [Related]
6. Antimicrobial susceptibilities of 40 isolates of Bacillus anthracis isolated in Turkey.
Esel D; Doganay M; Sumerkan B
Int J Antimicrob Agents; 2003 Jul; 22(1):70-2. PubMed ID: 12842331
[TBL] [Abstract][Full Text] [Related]
7. [Fluoroquinolones: antimicrobial activity and chemotherapeutic efficacy with respect to various pathogens in highly dangerous diseases].
Bondareva TA; Kalininskiĭ VB; Borisevich IV; Bondarev VP; Kozhukhov VV; Amosov MIu; Baramzina GV; Fomenkov OO; Krinitsyn FV
Antibiot Khimioter; 2007; 52(11-12):21-4. PubMed ID: 19275053
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetic considerations and efficacy of levofloxacin in an inhalational anthrax (postexposure) rhesus monkey model.
Kao LM; Bush K; Barnewall R; Estep J; Thalacker FW; Olson PH; Drusano GL; Minton N; Chien S; Hemeryck A; Kelley MF
Antimicrob Agents Chemother; 2006 Nov; 50(11):3535-42. PubMed ID: 17065619
[TBL] [Abstract][Full Text] [Related]
9. Bactericidal activity of levofloxacin, gatifloxacin, penicillin, meropenem and rokitamycin against Bacillus anthracis clinical isolates.
Drago L; De Vecchi E; Lombardi A; Nicola L; Valli M; Gismondo MR
J Antimicrob Chemother; 2002 Dec; 50(6):1059-63. PubMed ID: 12461034
[TBL] [Abstract][Full Text] [Related]
10. Postexposure Prophylaxis and Treatment of Bacillus anthracis Infections: A Systematic Review and Meta-analyses of Animal Models, 1947-2019.
Kennedy JL; Bulitta JB; Chatham-Stephens K; Person MK; Cook R; Mongkolrattanothai T; Shin E; Yu P; Negron ME; Bower WA; Hendricks K
Clin Infect Dis; 2022 Oct; 75(Suppl 3):S379-S391. PubMed ID: 36251546
[TBL] [Abstract][Full Text] [Related]
11. Maximizing efficacy and reducing the emergence of resistance.
Wise R
J Antimicrob Chemother; 2003 May; 51 Suppl 1():37-42. PubMed ID: 12702702
[TBL] [Abstract][Full Text] [Related]
12. Susceptibility of Bacillus anthracis to eleven antimicrobial agents including novel fluoroquinolones and a ketolide.
Frean J; Klugman KP; Arntzen L; Bukofzer S
J Antimicrob Chemother; 2003 Aug; 52(2):297-9. PubMed ID: 12865385
[TBL] [Abstract][Full Text] [Related]
13.
Steenbergen J; Tanaka SK; Miller LL; Halasohoris SA; Hershfield JR
Antimicrob Agents Chemother; 2017 May; 61(5):. PubMed ID: 28223382
[TBL] [Abstract][Full Text] [Related]
14. [Comparative evaluation of the effectiveness of fluoroquinolones in experimental anthrax infection].
D'iakov SI; Katsalukha VV; Lebedeva IK; Lukashina AV; Raĭskaia VA
Antibiot Khimioter; 1994 Jun; 39(6):15-9. PubMed ID: 7848000
[TBL] [Abstract][Full Text] [Related]
15. [Pharmacodynamic and pharmacokinetic evaluation of respiratory fluoroquinolones. Guideline to selection of the most appropriate fluoroquinolone].
Parra-Ruiz J; Hernández-Quero J
Rev Esp Quimioter; 2012 Dec; 25(4):245-51. PubMed ID: 23303254
[TBL] [Abstract][Full Text] [Related]
16. Impact of spores on the comparative efficacies of five antibiotics for treatment of Bacillus anthracis in an in vitro hollow fiber pharmacodynamic model.
Louie A; VanScoy BD; Brown DL; Kulawy RW; Heine HS; Drusano GL
Antimicrob Agents Chemother; 2012 Mar; 56(3):1229-39. PubMed ID: 22155821
[TBL] [Abstract][Full Text] [Related]
17. Anthrax: safe treatment for children.
Benavides S; Nahata MC
Ann Pharmacother; 2002 Feb; 36(2):334-7. PubMed ID: 11847958
[TBL] [Abstract][Full Text] [Related]
18. Management of anthrax meningitis.
Sejvar JJ; Tenover FC; Stephens DS
Lancet Infect Dis; 2005 May; 5(5):287-95. PubMed ID: 15854884
[TBL] [Abstract][Full Text] [Related]
19. Pharmacodynamic evaluation of tosufloxacin against Streptococcus pneumoniae in an in vitro model simulating serum concentration.
Fukuda Y; Takahata M; Mitsuyama J
J Infect Chemother; 2006 Feb; 12(1):1-8. PubMed ID: 16506083
[TBL] [Abstract][Full Text] [Related]
20. Anthrax attack in the USA.
McCarthy M
Lancet Infect Dis; 2001 Dec; 1(5):288-9. PubMed ID: 11871791
[No Abstract] [Full Text] [Related]
[Next] [New Search]
